1. ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). (12th June 2019) Authors: Sehn, L.H.; Flowers, C.; McMillan, A.; Morschhauser, F.; Salles, G.; Felizzi, F.; Launonen, A.; Qayum, N.; Thuresson, P.O. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗